替吉奥胶囊联合奥沙利铂治疗晚期结直肠癌疗效及对患者血清TGF-β1与Smad的影响观察  

Efficacy and Safety of Tegafur,Gineracil and Oteracil Potassium Capsules Combined with Oxaliplatin in the Treatment of Advanced Colorectal Cancer and Its Effect on Serum TGF-β1 and Smad

作　　者：单丹妮[1] 宋芳华[1] 姜雪滨[1] 尹晓芹[1] 王纪文[2] Shan Danni;Song Fanghua;Jiang Xuebin;Yin Xiaoqin;Wang Jiwen(Department of Oncology,Xinhua Hospital Affiliated to Dalian University,Dalian 116021,Liaoning,China;Depaitment of Cardiology,The Second Hospital of Dalian Medical University)

机构地区：[1]大连大学附属新华医院肿瘤科,辽宁大连116021 [2]大连医科大学附属第二医院心内科

出　　处：《药物流行病学杂志》2021年第4期235-238,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:观察替吉奥联合奥沙利铂治疗晚期结直肠癌疗效,及对患者血清转化生长因子β1(TGF-β1)和Smad蛋白的影响。方法:晚期结直肠癌患者60例随机分为观察组和对照组,每组30例。观察组给予口服替吉奥联合静滴奥沙利铂的治疗方案,对照组采用mFOLFOX6化疗方案。两组按各自方案至少治疗2个周期,每6周进行疗效评价。观察两组治疗后的临床疗效、生存时间、药品不良反应发生情况,比较两组治疗前后生活质量评分和血清TGF-β1、Smad-3和Smad-7水平变化。结果:观察组总有效率为70.00%,显著高于对照组的33.33%(P<0.05);观察组无进展生存期(PFS)和总生存期均明显长于对照组(P<0.05)。治疗后,两组患者生活质量评分和血清Smad-7水平均较前升高,血清TGF-β1、Smad-3水平则较前降低(P<0.05);且观察组各项指标均优于对照组(P<0.05)。两组药品不良反应差异无统计学意义(P>0.05)。结论:替吉奥联合奥沙利铂能调节晚期结直肠癌患者的血清TGF-β1、Smad水平,疗效显著且安全性好,值得临床推广使用。Objective:To observe the curative effect of tegafur,gineracil and oteracil potassium capsules combined with oxaliplatin in the treatment of advanced colorectal cancer,and its effect on serum transforming growth factor-β1(TGF-β1)and Smad protein.Methods:Totally 60 patients with advanced colorectal cancer were randomly divided into the observation group and the control group,30 patients in each group.The observation group was treated with tegafur,gineracil and oteracil potassium capsules combined with oxaliplatin,while the control group was treated with mFOLFOX6.The clinical efficacy,survival time,quality of life score and adverse reactions of the two groups were observed after treatment,as well as the serum TGF-β1,Smad-3 and Smad-7 influence.Results:The total effective rate of the observation group was 70.00%,which was significantly higher than 33.33%of the control group(P<0.05);the progression free survival(PFS)and overall survival of the observation group were significantly longer than those of the control group(P<0.05).After treatment,the quality of life score and serum Smad-7 level of the two groups were higher than before,while the serum TGF-β1 and Smad-3 levels were lower than before(P<0.05),and the indexes of the observation group were better than those of the control group(P<0.05).There was no significant difference in adverse drug reactions between the two groups(P>0.05).Conclusion:Tegafur,gineracil and oteracil potassium capsules combined with oxaliplatin can regulate the levels of TGF-β1 and Smad in patients with advanced colorectal cancer.

关 键 词：替吉奥胶囊 奥沙利铂 晚期结直肠癌 转化生长因子β1 SMAD蛋白 

分 类 号：R979.1[医药卫生—药品]